1-5 of 5
Lisbeth Enggaard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Carsten Utoft Niemann, Julie Dubois, Christian Brieghel, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens Mellink, Johan A Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Kazem Nasserinejad, Hoa Thi Tuyet Tran, Mark-David Levin, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 69.
https://doi.org/10.1182/blood-2021-148630
Published: 2021
Journal Articles

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Carsten U. Niemann, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H. M. Mellink, Johan A. Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Kazem Nasserinejad, Arnon P. Kater
Journal: Blood
Blood (2021) 137 (8): 1117–1120.
https://doi.org/10.1182/blood.2020008608
Published: 2021
Includes: Supplemental data
Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Carsten Utoft Niemann, MD PhD, Julie Dubois, Sabina Kersting, MD PhD, Lisbeth Enggaard, MD, Gerrit J Veldhuis, Rogier Mous, MD PhD, Clemens Mellink, PhD, Johan A Dobber, Christian Bjørn Poulsen, MD, Henrik Frederiksen, MD Prof, Ann Janssens, Ida Schjødt, MD PhD, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, MD, Mar Bellido, Hoa T Tran, Kazem Nasserinejad, Mark-David Levin, MD PhD, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4292.
https://doi.org/10.1182/blood-2019-124377
Published: 2019
Journal Articles

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Kathrine Aarup, Lisbeth Enggaard, MD, Robert Schou Pedersen, MD PhD, Rasmus Heje Thomsen, Olav Jonas Bergmann, Mikael Frederiksen, Ilse Christiansen, Tine Nielsen, Henrik Frederiksen, MD Prof, Carsten Utoft Niemann, MD PhD Ass. Prof, Michael Asger Andersen, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1767.
https://doi.org/10.1182/blood-2019-123011
Published: 2019